Comparison Between Body Mass Index and Side Effect Incidence in Bladder Cancer Patients Treated with Gemcitabine-Cisplatin at Dr. Saiful Anwar General Hospital Malang, Indonesia

Authors

  • Kurnia Penta Seputra Brawijaya University, School of Medicine, Department of Urology, Dr. Saiful Anwar General Hospital Malang, Indonesia. Author
  • Astarin Ardiani Brawijaya University, School of Medicine, Department of Urology, Dr. Saiful Anwar General Hospital Malang, Indonesia. Author
  • Besut Daryanto Brawijaya University, School of Medicine, Department of Urology, Dr. Saiful Anwar General Hospital Malang, Indonesia. Author

DOI:

https://doi.org/10.61841/qj6fwj11

Keywords:

BMI, bladder cancer, Gemcitabine-Cisplatin, side effects

Abstract

Gemcitabine-Cisplatin chemotherapy is one of bladder cancer treatment available in Dr. Saiful Anwar General Hospital Malang, although chemotherapy are beneficent, it also gave many unwanted side effect. Body Mass Index (BMI) said to have roles in cancer development and therapy outcome. This study aimed to compare BMI with side effect incidence in bladder cancer patients receiving six course of Gemcitabine- Cisplatin chemotherapy. Eighteen bladder cancer patients receiving Gemcitabine-Cisplatin chemotherapy by urology oncologist from 2016 to 2018 were recorded. The patients were followed during their six series of chemotherapy and any possible side effect were recorded. The data then analysed with chi square and T-test using SPSS programme. Body mass index (BMI) including normal weight, underweight, overweight and obese, account to 73.3%; 6.67%; 13.3%; and 6.67% respectively . Pathology finding consist of Transitional Cell Carcinoma high grade (46.7%) and low grade (53.3%). All 15 patients underwent six series of Gemcitabine-Cisplatin chemotherapy, side effects occurred during the whole series including, nausea(80%), fatigue(87%), vomiting(27%), alopecia(13.3%), infection(20%). Hematologic side effect including anemia, leucopenia, thrombocytopenia and nephrotoxicity Hematologic side effects such as: anemia, leucopenia and thrombocytopenia and also nephrotoxicity occurred in all 15 patients, minimally once of the six series of chemotherapy. When those side effect compared with BMI there were no statistical significant between the them with (p = 0.360), (p = 0.310), (p = 0.634), and (p = 0.423) respectively. Body Mass Index has no relation with side effect occurrence in bladder cancer patients receiving Gemcitabine-Cisplatin chemotherapy.

 

Downloads

Download data is not yet available.

References

1. Westhoff E, Witjes JA, Fleshner NE, Lerner SP, Shariat SF, Steineck G, et al. Body Mass Index, Diet- Related Factors, and Bladder Cancer Prognosis: A Systematic Review and Meta-Analysis. Bl Cancer [Internet]. 2018;4(1):91–112. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29430510%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcg i?artid=PMC5798521%0Ahttp://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/BL C-170147

2. Costantini C, Millard F. Update on Chemotherapy in the Treatment of Urothelial Carcinoma. Sci World J [Internet]. 2011;11:1981–94. Available from: http://www.hindawi.com/journals/tswj/2011/590175/

3. Wang Y, Probin V, Zhou D. Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy. Curr Cancer Ther Rev [Internet]. 2006;2(3):271–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19936034%5Cnhttp://www.pubmedcentral.nih.gov/articlerender.fc gi?artid=PMC2779029%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/19936034%5Cnhttp://www.pubmedc entral.nih.gov/articlerender.fcgi?artid=PMC2779029

4. Cognetti F, Ruggeri EM, Felici A, Gallucci M, Muto G, Pollera CF, et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: An italian, multicenter, randomized phase iii trial. Ann Oncol. 2012;23(3):695–700.

5. Ismaili N, Amzerin M, Flechon A. Chemotherapy in advanced bladder cancer: current status and future. J Hematol Oncol [Internet]. 2011;4(1):35. Available from: http://jhoonline.biomedcentral.com/articles/10.1186/1756-8722-4-35

6. Letaiová S, Medveová A, Ovíková A, Duinská M, Volkovová K, Mosoiu C, et al. Bladder cancer, a review of the environmental risk factors. Environ Heal A Glob Access Sci Source. 2012;11(SUPPL.1):1–5.

7. Hansel DE, Amin MB, Comperat E, Cote RJ, Knüchel R, Montironi R, et al. A contemporary update on pathology standards for bladder cancer: Transurethral resection and radical cystectomy specimens. Eur Urol. 2013;63(2):321–32.

8. Hourdequin KC, Schpero WL, McKenna DR, Piazik BL, Larson RJ. Toxic effect of chemotherapy dosing using actual body weight in obese versus normal-weight patients: A systematic review and meta-analysis. Ann Oncol. 2013;24(12):2952–62.

9. Wang, J.-H., Zhou, P., Li, Y.-Q., Sun, J.-J., Tan, W.-J., Huang, C.-C., Yu, X.-Y., Liu, C.-Z., Luo, H.-

L.Modification of atrioventricular node in a special condition treating paroxysmal supraventricular tachycardia(2010) Journal of Cardiovascular Disease Research, 1 (4), pp. 210-212. DOI: 10.4103/0975- 3583.74266

10. Mohammed, I.A., Hendi, S.A., Naji, A.Z.Evaluation of immunological and biochemical background for the occurrence of dental caries in B-thalassemic patients(2018) International Journal of Pharmaceutical Research, 10 (4), pp. 27-34.

11. Baldi A. "Computational Approaches for Drug Design and Discovery: An Overview." Systematic Reviews in Pharmacy 1.1 (2010), 99-105. Print. doi:10.4103/0975-8453.59519

Downloads

Published

31.10.2020

Issue

Vol. 24 No. 8 (2020): 24 (8) 2020

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  1. Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
  2. Adapt — remix, transform, and build upon the material for any purpose, even commercially.
  3. The licensor cannot revoke these freedoms as long as you follow the license terms.

Under the following terms:

  1. Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  2. No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Notices:

You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .

No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.

How to Cite

Seputra, K. P., Ardiani, A., & Daryanto, B. (2020). Comparison Between Body Mass Index and Side Effect Incidence in Bladder Cancer Patients Treated with Gemcitabine-Cisplatin at Dr. Saiful Anwar General Hospital Malang, Indonesia. International Journal of Psychosocial Rehabilitation, 24(8), 1-5. https://doi.org/10.61841/qj6fwj11